GILD / Dow Jones Newswires: Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America more_horizontal

Gilead Sciences (GILD) closed at $77.88 in the latest trading session, marking a +1.64% move from the prior day. more_horizontal

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its third-quarter 2023 resul more_horizontal

Gilead Sciences (GILD) concluded the recent trading session at $78.15, signifying a +0.76% move from its prior day's close. more_horizontal

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant develop more_horizontal

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). Bu more_horizontal

Gilead Sciences Inc. GILD, +2.00% announced Tuesday a 12-year partnership Assembly Biosciences Inc. ASMB, +2.11% to develop antiviral therapies, with more_horizontal

Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis more_horizontal